PURPOSE: Chemoradiotherapy using 5-fluorouracil has shown to be effective treatment for rectal cancer. Thymidylate synthase (TS) is an important target enzyme for the fluoropyrimidines. However, the predictive role of TS levels in early stage rectal cancer is not yet well understood. We analyzed the value of TS gene polymorphisms as a predictive marker in patients with stage II and III rectal cancer treated with preoperative concomitant radiotherapy and fluoropyrimidine-based chemotherapy. METHODS AND MATERIALS: Between 1998 and 2007, blood samples were obtained from 51 patients with stage II/III rectal cancer. Forty patients were T2-3 (78%), 11 were T4 (22%), and 59% were N+. DNA was extracted from peripheral blood, and the genotypes were analyzed using PCR-restriction fragment length polymorphism and automated sequencing techniques. RESULTS: The *3/*3 thymidylate synthase genotype was associated with a higher response rate (pathological complete remission and microfoci residual tumor; 61 vs. 22% in *2/*2 and *2/*3; P = 0.013). In the multivariate analysis, the *3/*3 thymidylate synthase genotype was also an independent prognostic factor for better survival (P < 0.05). CONCLUSIONS: The thymidylate synthase genotype might help to identify patients with stage II/III rectal cancer who could benefit from pre- and postoperative fluorouracil-based chemotherapy.
PURPOSE: Chemoradiotherapy using 5-fluorouracil has shown to be effective treatment for rectal cancer. Thymidylate synthase (TS) is an important target enzyme for the fluoropyrimidines. However, the predictive role of TS levels in early stage rectal cancer is not yet well understood. We analyzed the value of TS gene polymorphisms as a predictive marker in patients with stage II and III rectal cancer treated with preoperative concomitant radiotherapy and fluoropyrimidine-based chemotherapy. METHODS AND MATERIALS: Between 1998 and 2007, blood samples were obtained from 51 patients with stage II/III rectal cancer. Forty patients were T2-3 (78%), 11 were T4 (22%), and 59% were N+. DNA was extracted from peripheral blood, and the genotypes were analyzed using PCR-restriction fragment length polymorphism and automated sequencing techniques. RESULTS: The *3/*3 thymidylate synthase genotype was associated with a higher response rate (pathological complete remission and microfoci residual tumor; 61 vs. 22% in *2/*2 and *2/*3; P = 0.013). In the multivariate analysis, the *3/*3 thymidylate synthase genotype was also an independent prognostic factor for better survival (P < 0.05). CONCLUSIONS: The thymidylate synthase genotype might help to identify patients with stage II/III rectal cancer who could benefit from pre- and postoperative fluorouracil-based chemotherapy.
Authors: N A Janjan; V S Khoo; J Abbruzzese; R Pazdur; R Dubrow; K R Cleary; P K Allen; P M Lynch; G Glober; R Wolff; T A Rich; J Skibber Journal: Int J Radiat Oncol Biol Phys Date: 1999-07-15 Impact factor: 7.038
Authors: E Villafranca; Y Okruzhnov; M A Dominguez; J García-Foncillas; I Azinovic; E Martínez; J J Illarramendi; F Arias; R Martínez Monge; E Salgado; S Angeletti; A Brugarolas Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Christiane Jakob; Torsten Liersch; Wolfdietrich Meyer; Gustavo B Baretton; Peter Häusler; Wolfgang Schwabe; Heinz Becker; Daniela E Aust Journal: Am J Surg Pathol Date: 2005-10 Impact factor: 6.394
Authors: Jan Stoehlmacher; Eray Goekkurt; Ulrike Mogck; Daniela E Aust; Michael Kramer; Gustavo B Baretton; Torsten Liersch; Gerhard Ehninger; Christiane Jakob Journal: Cancer Lett Date: 2008-08-21 Impact factor: 8.679
Authors: Cathryn Rankin; Adetunji T Toriola; Cornelia M Ulrich; Karen W Makar; Özge Altug-Teber; Jacqueline K Benedetti; Rebecca S Holmes; Stephen R Smalley; Charles D Blanke; Heinz-Josef Lenz Journal: Cancer Date: 2014-07-15 Impact factor: 6.860
Authors: Lena-Christin Conradi; Annalen Bleckmann; Markus Schirmer; Thilo Sprenger; Peter Jo; Kia Homayounfar; Hendrik A Wolff; Hilka Rothe; Peter Middel; Heinz Becker; Michael B Ghadimi; Tim Beissbarth; Torsten Liersch Journal: Ann Surg Oncol Date: 2011-02-23 Impact factor: 5.344